XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in IsraelGlobeNewsWire • 10/20/23
XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyGlobeNewsWire • 10/20/23
Dr. Morris C. Laster Files Preliminary Proxy Statement Nominating Two Highly-Qualified Individuals For Election To Board At Scopus BioPharma Inc.'s 2021 Annual MeetingPRNewsWire • 09/20/21